These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 8723151)
1. Assessment of coenzyme Q10 tolerability in Huntington's disease. Feigin A; Kieburtz K; Como P; Hickey C; Claude K; Abwender D; Zimmerman C; Steinberg K; Shoulson I Mov Disord; 1996 May; 11(3):321-3. PubMed ID: 8723151 [TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. ; Hyson HC; Kieburtz K; Shoulson I; McDermott M; Ravina B; de Blieck EA; Cudkowicz ME; Ferrante RJ; Como P; Frank S; Zimmerman C; Cudkowicz ME; Ferrante K; Newhall K; Jennings D; Kelsey T; Walker F; Hunt V; Daigneault S; Goldstein M; Weber J; Watts A; Beal MF; Browne SE; Metakis LJ Mov Disord; 2010 Sep; 25(12):1924-8. PubMed ID: 20669312 [TBL] [Abstract][Full Text] [Related]
3. A controlled trial of idebenone in Huntington's disease. Ranen NG; Peyser CE; Coyle JT; Bylsma FW; Sherr M; Day L; Folstein MF; Brandt J; Ross CA; Folstein SE Mov Disord; 1996 Sep; 11(5):549-54. PubMed ID: 8866496 [TBL] [Abstract][Full Text] [Related]
4. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Koroshetz WJ; Jenkins BG; Rosen BR; Beal MF Ann Neurol; 1997 Feb; 41(2):160-5. PubMed ID: 9029064 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of levetiracetam in Huntington disease. de Tommaso M; Di Fruscolo O; Sciruicchio V; Specchio N; Cormio C; De Caro MF; Livrea P Clin Neuropharmacol; 2005; 28(6):280-4. PubMed ID: 16340384 [TBL] [Abstract][Full Text] [Related]
6. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Landwehrmeyer GB; Dubois B; de Yébenes JG; Kremer B; Gaus W; Kraus PH; Przuntek H; Dib M; Doble A; Fischer W; Ludolph AC; Ann Neurol; 2007 Sep; 62(3):262-72. PubMed ID: 17702031 [TBL] [Abstract][Full Text] [Related]
9. A controlled trial of remacemide hydrochloride in Huntington's disease. Kieburtz K; Feigin A; McDermott M; Como P; Abwender D; Zimmerman C; Hickey C; Orme C; Claude K; Sotack J; Greenamyre JT; Dunn C; Shoulson I Mov Disord; 1996 May; 11(3):273-7. PubMed ID: 8723144 [TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Cady R; Schreiber C Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501 [TBL] [Abstract][Full Text] [Related]
11. The relationship between CAG repeat length and clinical progression in Huntington's disease. Ravina B; Romer M; Constantinescu R; Biglan K; Brocht A; Kieburtz K; Shoulson I; McDermott MP Mov Disord; 2008 Jul; 23(9):1223-7. PubMed ID: 18512767 [TBL] [Abstract][Full Text] [Related]
12. Assessment of adaptive functioning in Huntington's disease. Bylsma FW; Rothlind J; Hall MR; Folstein SE; Brandt J Mov Disord; 1993 Apr; 8(2):183-90. PubMed ID: 8474487 [TBL] [Abstract][Full Text] [Related]
13. Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease. Kasparová S; Sumbalová Z; Bystrický P; Kucharská J; Liptaj T; Mlynárik V; Gvozdjáková A Neurochem Int; 2006 Jan; 48(2):93-9. PubMed ID: 16290265 [TBL] [Abstract][Full Text] [Related]
15. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Pastores GM; Barnett NL; Kolodny EH Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246 [TBL] [Abstract][Full Text] [Related]
16. Minocycline in Huntington's disease: a pilot study. Thomas M; Ashizawa T; Jankovic J Mov Disord; 2004 Jun; 19(6):692-5. PubMed ID: 15197710 [TBL] [Abstract][Full Text] [Related]
17. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease. Zesiewicz TA; Sullivan KL; Hauser RA; Sanchez-Ramos J Mov Disord; 2006 Nov; 21(11):1998-2001. PubMed ID: 16941461 [TBL] [Abstract][Full Text] [Related]
18. CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease. Dubinsky R; Gray C Mov Disord; 2006 Apr; 21(4):530-3. PubMed ID: 16258942 [TBL] [Abstract][Full Text] [Related]